Physician profile
Steven J Repitor
NPI 1689601353
$5,515.21
in general payments reported to CMS, 2019-2025
36 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $212 · 2021: $1,947 · 2022: $873 · 2023: $872 · 2024: $610 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Debt Forgiveness: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.01 |
| Debt Forgiveness | $275.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle, INC | $1,240.49 | 2021-2022 | |
| Smith+Nephew, INC. | $671.04 | 2019-2025 | Grafix Pl, Collagenase Santyl, Stravix |
| Bard Peripheral Vascular, INC. | $485.08 | 2019-2024 | Venclose Maven Catheter |
| Inari Medical, INC. | $415.94 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Djo, LLC | $275.75 | 2023 | |
| Stryker Corporation | $263.39 | 2021-2024 | Prophecy, Prostep Mica, Augment Injectable |
| Avinger INC. | $251.28 | 2019-2022 | |
| Paragon 28, INC. | $223.83 | 2019-2021 | |
| Kerecis Limited | $172.63 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Cardiovascular Systems INC. | $171.44 | 2020-2021 | |
| Treace Medical Concepts, INC. | $145.11 | 2022-2023 | |
| Acumed LLC | $131.75 | 2021 | |
| Osiris Therapeutics INC. | $128.77 | 2019 | |
| Biotissue Holdings INC. | $125.87 | 2023 | |
| Anika Therapeutics, INC. | $123.17 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $102.49 | 2025 | Exogen Ultrasound Bone Healing System |
| Glaxosmithkline, LLC. | $74.85 | 2020-2021 | |
| Exact Sciences Corporation | $54.33 | 2023-2025 | Cologuard Collection Kit |
| Kci USA, INC. | $48.62 | 2021-2023 | Activ.A.C. |
| Depuy Synthes Sales INC. | $45.50 | 2019 | |
| Organogenesis INC. | $44.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $36.14 | 2024 | Nuzyra |
| Lilly USA, LLC | $31.35 | 2024 | Zepbound, Mounjaro |
| Ucb, INC. | $30.13 | 2022-2024 | Nayzilam |
| Abbvie INC. | $29.24 | 2022 | |
| Hydrofera LLC | $23.27 | 2024 | Hydrofera Blue Ready - Border |
| Aimmune Therapeutics, INC. | $19.73 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.71 | 2025 | Xifaxan |
| Acell, INC. | $19.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.98 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $17.71 | 2021 | |
| Convatec INC. | $17.64 | 2021 | |
| Merck Sharp & Dohme LLC | $17.39 | 2022 | |
| Solventum Corporation | $14.15 | 2025 | Activ.A.C. |
| Radius Health, INC. | $12.95 | 2020 | |
| Arthrosurface Incorporated | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Repitor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.